Major histocompatibility complex class II-insulin B-chain (9-23) epitope complex (MHC II-InsB:9-23)

The Major histocompatibility complex class II-insulin B-chain (9-23) epitope complex is a pivotal immunological target in the development of Type 1 Diabetes (T1D). This complex forms when specific MHC class II alleles, most notably HLA-DQ8 and HLA-DQ2 in humans, present a fragment of the insulin B-chain (residues 9-23) to CD4+ T cells (Nakayama et al., Nature, 2005; Michels et al., JBC, 2011). The recognition of this peptide-MHC (pMHC) complex by autoreactive T-cell receptors (TCRs) initiates the destruction of insulin-producing beta cells in the pancreatic islets (Yu et al., PNAS, 2000). Because this interaction is highly specific to the early stages of T1D pathogenesis, it serves as a primary focus for antigen-specific immunotherapies. Current therapeutic strategies aim to modulate this interaction to restore immune tolerance rather than providing broad immunosuppression. These approaches include the use of soluble pMHC complexes, DNA vaccines encoding the epitope (e.g., NNC0361-0027), and nanoparticle-based platforms like Navacims that present the complex to induce the expansion of regulatory T cells (Santamaria, Nature Reviews Drug Discovery, 2017). Additionally, monoclonal antibodies like Teplizumab modulate the T-cell response to this complex by targeting the CD3 epsilon chain on the TCR complex. By specifically interfering with the MHC II-insulin B:9-23/TCR axis, these therapies seek to preserve endogenous insulin production in at-risk individuals and newly diagnosed patients.

Other names

HLA-DQ8-insulin B:9-23 complexHLA-DQ2-insulin B:9-23 complexpMHC II-insulin B epitopeInsulin B:9-23/MHC II complexI-Ag7-insulin B:9-23 (murine analog)

Induction of antigen-specific immune tolerance through the presentation of the insulin B:9-23 epitope to autoreactive CD4+ T cells in a non-inflammatory context, promoting the differentiation of regulatory T cells (Tregs) and the deletion or anergy of pathogenic effector T cells.